No Data
Zymeworks Engages Investors, Awaits Drug Approval
Zymeworks Announces Participation in Upcoming Investor Conferences
Buy Rating on Zymeworks Stock Amid Anticipated Zani Approval and Strategic Capital Allocation
News Flash: Analysts Just Made A Captivating Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Forecasts
Analysts Conflicted on These Healthcare Names: Henry Schein (HSIC), Zymeworks (ZYME) and Rocket Pharmaceuticals (RCKT)
Augurex Life Sciences Corp. Names Healthcare Leader Neil Klompas to Succeed Co-Founder Dr. Norma Biln as President and CEO